69results about "Micromachined delivery" patented technology

An embodiment relates to an active implantable medical device (AIMD), comprising: a permeability module that allows ingress flow of a fluid to an osmotic agent chamber and generates osmotic pressure; a piston that moves longitudinally within the active implantable medical device (AIMD) in response to the osmotic pressure; a drug chamber that comprises a drug and a valve module to allow one-way flow of the drug from the drug chamber to outside the active implantable medical device (AIMD); a sensor module that measures a displacement of the piston in real-time; and an electronic module that communicates a signal to the valve module to control the valve module and regulate the one-way flow of the drug based on the displacement of the piston.

The present invention relates to a device for mucosal and transmucosal drug delivery providing a controlled release of active pharmaceutical ingredients. The drug delivery device has a drug reservoir containing an active pharmaceutical ingredient loaded on graphene and / or its derivatives, such as graphene oxide, and a microcontroller able to connect to an electronic device. The release of the active pharmaceutical ingredient from the drug reservoir is controlled by the microcontroller. The device can also include a biosensor system to collect biometric information in order to interact with the drug delivery in a closed-loop system.

The invention relates to a graphene hydrogel neural microelectrode and a preparation method thereof.The neural microelectrode comprises a long-strip-shaped electrode body, the electrode body comprises an insulating substrate layer, a conductive layer and an insulating covering layer, and the conductive layer is wrapped and sealed by the insulating substrate layer and the insulating covering layer; a contact window is arranged at one end, close to the electrode body, of the insulating covering layer, a conductive expansion layer made of graphene hydrogel is arranged below the contact window and the insulating covering layer on the periphery of the contact window, the conductive expansion layer is electrically connected with the conductive layer, and the conductive expansion layer can expand after being heated or absorbing water to form an electrode contact protruding outwards from the contact window. Amino multi-walled carbon nanotubes, amino graphene quantum dots and gold nanoparticles are loaded in the graphene hydrogel. The electrode contact has the advantages that after the electrode contact is heated or absorbs water, the conductive expansion layer expands to form the electrode contact protruding out of the contact window, and the electrode contact is good in tissue affinity, capable of making better contact with nervous tissue and more excellent in performance.

A system for targeted delivery of a medicament to the gastrointestinal tract (e.g., selectively to the duodenum) of a subject. The system includes a medicament, a mucoadhesive layer at least partially surrounding the medicament, and an enteric coating encasing the medicament and mucoadhesive layer. The enteric coating comprises a material degradable by a pH of the GI tract and a material digestible by a lipase. Also provided are method of making and using the system for targeted delivery of a medicament to the gastrointestinal tract. Also provided are a system for deploying a medicament-containing needle system using an expanding element. The system includes a medicament-containing needle system and an expanding element within a capsule. The capsule is initially coated with an enteric coating. As the enteric coating degrades the expanding element absorbs fluid that enters the capsule and expands to deploy the medicament-containing needle system from the capsule.

Provided are systems and miniature devices configured to navigate within a patient to a location therewithin for delivering to induce a localized therapeutic effect, such as the delivery of catalyzing energy and / or for the conversion of a prodrug to a pharmaceutically active drug. Further provided are various methods of treatment using such systems and devices.

Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and / or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and / or degraded within the GI tract.

Aspects of the present disclosure relate to an article. In some embodiments, the article is a gastric retention device or a gastrointestinal device. In some embodiments, the article comprises one or more reservoirs comprising a therapeutic payload. In some embodiments, the article comprises one or more triggerable release mechanisms. In some embodiments, the triggerable release mechanism comprises a metal seal. In some embodiments, release of the therapeutic payload is accomplished via electrochemical dissolution of the metal seal. Other aspects of the disclosure relate to methods for delivering a drug using the drug delivery articles disclosed herein.

A subcutaneous implant comprises a body formed from a biodegradable polymer and defining a plurality of reservoirs, each reservoir having an opening. Each reservoir contains a pre-determined quantity of therapeutic agent, or pre-determined quantity of a combination of therapeutic agent and biodegradable polymer or carrier. A cap covers the opening of at least one of the plurality of reservoirs, the cap comprising a biodegradable polymer formulated to degrade upon exposure to the tissue of the subject, permitting the contents of the capped reservoir to be released into the tissue of a subject at a predetermined time after the subcutaneous implant is inserted beneath the skin of a subject. The body, therapeutic agent, combination of therapeutic agent and biodegradable polymer or carrier, and said cap dissolve over time, eliminating the need to remove the implant. The body of the implant may consist essentially of a biodegradable polymer and does not contain or include a therapeutic agent. The contents of the capped reservoir or reservoirs cannot escape from the reservoir until a predetermined time.

An embodiment relates to a system comprising a fluid chamber containing a fluid; an Active Wearable Medical Device (AWMD) comprising a permeability module configured to allow ingress of fluid from the fluid chamber to an osmotic agent chamber via a semi-permeable membrane to generate osmotic pressure; a piston that moves longitudinally in response to the osmotic pressure; a drug chamber comprising a drug and a valve module configured to enable one-way drug flow from the chamber to outside the AWMD; a sensor module to measure piston displacement and provide real-time data; and an electronic module configured to regulate drug ejection based on the displacement data, ensuring dose-to-dose volume variation remains within ±25%. A machine learning model triggers alerts if dosing deviates from threshold limits. A channel is fluidically coupled to the AWMD and delivers the drug to the subject. The AWMD is externally worn and not implanted.

The present disclosure provides a drug delivery device. The drug delivery device is orally ingested by a patient and then actuated within the patient's gastrointestinal (GI) tract. Upon actuation, the arms of the drug delivery device extend, causing the piercing tip to penetrate the GI tract wall. A driver then drives a plunger within the drug delivery device, pushing the drug through the piercing tip and the patient's GI tract wall. After a period of time, a portion of the drug delivery device dissolves, allowing the drug delivery device to pass through the GI tract.

The present disclosure provides a drug delivery device. The drug delivery device is orally ingested by a patient and then actuated within the patient's gastrointestinal (GI) tract. Upon actuation, resilient arms within the drug delivery device expand and engage the GI tract wall. A driver then drives a plunger within the drug delivery device, pushing the drug through a channel in the resilient arms and through the patient's GI tract wall. After a period of time, at least a portion of the drug delivery device dissolves, and the drug delivery device passes through the GI tract.

Drug delivery devices and methods of controlled drug delivery to a patient are provided. The drug delivery device may include one or two microchip elements, each of which has a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release apertures are closed off by one or more reservoir caps which can be electrically activated to open the drug release apertures. The drug delivery device also includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced a distance from an exterior wall of the body portion of the microchip element, the outer housing includes the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the exterior wall of the body portion of the microchip element.

The delivery device may include a capsule housing, at least one tissue-piercing member within a sealed compartment within the capsule housing, the at least one tissue-piercing member configured to release a payload, and an actuator within the capsule housing and at least partially outside the sealed compartment, the actuator configured to advance the at least one tissue-piercing member out of the sealed compartment.

The present invention provides drug delivery devices and methods for controlled drug delivery to a patient. The drug delivery devices can include one or two microchip elements, each having a body portion with one or more drug release apertures in fluid communication with at least one contained reservoir. The drug release apertures are closed by one or more reservoir covers that can be electrically activated to open the drug release apertures. The drug delivery devices further include (i) a drug formulation disposed in the at least one contained reservoir, and (ii) at least one drug permeable membrane. In some cases, an outer housing is spaced apart from an outer wall of the body portion of the microchip element, the outer housing includes the at least one drug permeable membrane, and defines a reservoir space between the drug permeable membrane and the outer wall of the body portion of the microchip element.

The object of the invention is a method for obtaining an injectable biocompatible drug delivery vehicle, cell carrier or combinations thereof, in the form of microscaffolds, characterised in that it comprises the following steps: a) preparation of a solution containing a polymer and at least one solvent; b) formation of fibres with a diameter of 50 nm to 10 pm on a flat collector by electrospinning; c) laser cutting of the nonwoven fabric formed on the collector into individual separate scaffold microscaffolds with a thickness of 0.01 to 0.2 mm and either a cylinder-form with a base diameter of 0.1 to 0.4 mm or a prism-form with a base edge length of 0.04 to 0.4 mm; d) separation of the microscaffolds from the collector; e) chemical modification of the microscaffolds by suspending them in an aqueous NaOH solution of 0.001-1 M concentration for 1-120 min or physical modification by suspending them in an aqueous protein solution of 0.001-0.5 M concentration for 2-120 min; f) removing excess NaOH or protein from the surface of the microscaffolds. A further object of the invention is an injectable delivery composition comprising a buffer and biocompatible in vitro mutually non-aggregating drug vehicles, cell carriers, or combinations thereof, characterised in that the vehicles / carriers are electrospun fibre microscaffolds fabricated with the method according to the invention, wherein each microscaffold is a single vehicle / carrier with a thickness of 0.005 to 0.2 mm and the shape of a cylinder with a base diameter of 0.05 to 0.5 mm or a prism with a base edge length of 0.05 to 0.5 mm, the surface of which is modified chemically with NaOH solution or physically with a protein solution, whereby the microscaffolds suspended in the buffer form a suspension of non-aggregating microparticles. Another object of the invention is the use of the composition according to the invention in the treatment of bone, cartilage, and intervertebral disc injuries.

To provide drug delivery devices and methods of controlled drug delivery to a patient.SOLUTION: A drug delivery device may include one or two microchip elements, each of which has a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release apertures are closed off by one or more reservoir caps which can be electrically activated to open the drug release apertures. The drug delivery device also includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced a distance from an exterior wall of the body portion of the microchip element, the outer housing includes the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the exterior wall of the body portion of the microchip element.SELECTED DRAWING: Figure 2

To provide an oral drug delivery device having expanding arms to be activated in the small intestine to deliver a drug through a gastrointestinal wall.SOLUTION: A drug delivery device 100 is taken orally by a patient, and then activates within the gastrointestinal (GI) tract of the patient. Upon activation, resilient arms 215 within the drug delivery device 100 expand and engage the GI tract walls. A driver then drives a plunger 340 within the drug delivery device 100, pushing a drug through a channel 213 in the resilient arms 215 and through the GI tract walls of the patient. After a period of time, at least a portion of the drug delivery device 100 dissolves and the drug delivery device 100 passes through the GI tract.SELECTED DRAWING: Figure 1

The present disclosure provides a drug delivery device. The drug delivery device is taken orally by a patient, and then activates within the gastrointestinal (GI) tract of the patient. Upon activation, arms of the drug delivery device expand, and penetrating tips penetrate the GI tract walls. A driver then drives a plunger within the drug delivery device, pushing a drug through the penetrating tips and through the GI tract walls of the patient. After a period of time, part of the drug delivery device dissolves and the drug delivery device passes through the GI tract.

Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and / or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and / or degraded within the GI tract.

Embodiments of the present invention are directed to a liquid delivery apparatus. A non-limiting example of the apparatus includes a substrate including a cavity formed in a surface of the substrate. The apparatus can also include a membrane disposed on the surface of the substrate covering an opening of the cavity. The apparatus can also include a hydrophobic layer disposed on the membrane. The apparatus can also include a seal disposed between the membrane and the substrate, wherein the seal surrounds the opening of the cavity. The apparatus can also include an electrode layer coupled to the membrane.

The present disclosure provides a drug delivery device. The drug delivery device is orally ingested by a patient and then activated within the patient's gastrointestinal (GI) tract. Upon activation, a resilient arm within the drug delivery device expands and engages the GI tract wall. A driver then drives a plunger within the drug delivery device, pushing a drug through a channel in the resilient arm and through the patient's GI tract wall. After a period of time, at least a portion of the drug delivery device dissolves, and the drug delivery device passes through the GI tract.

A subcutaneous implant comprises a body formed from a biodegradable polymer and defining a plurality of reservoirs, each reservoir having an opening. Each reservoir contains a pre-determined quantity of therapeutic agent, or pre-determined quantity of a combination of therapeutic agent and biodegradable polymer or carrier. A cap covers the opening of at least one of the plurality of reservoirs, the cap comprising a biodegradable polymer formulated to degrade upon exposure to the tissue of the subject, permitting the contents of the capped reservoir to be released into the tissue of a subject at a predetermined time after the subcutaneous implant is inserted beneath the skin of a subject. The body, therapeutic agent, combination of therapeutic agent and biodegradable polymer or carrier, and said cap dissolve over time, eliminating the need to remove the implant. The body of the implant may consist essentially of a biodegradable polymer and does not contain or include a therapeutic agent. The contents of the capped reservoir or reservoirs cannot escape from the reservoir until a predetermined time.

A method for identifying the presence or progression of hypoxic ischemic brain injury includes, for each subset of one or more subsets of a three-dimensional medical image of a head of a patient: (i) inputting said each subset into a machine-learning model, (ii) extracting one or more features or feature maps from the machine-learning model, and (iii) constructing, based on the one or more features or feature maps, one of a sequence of vectors. The sequence of vectors is then pooled to obtain a scan-level vector that is used to obtain a score indicating HIBI presence or progression in the patient. For example, the scan-level vector can be inputted into a pre-trained classifier that generates the score based on the scan-level vector. The machine-learning model may be a pre-trained conventional neural network or support vector machine.

The present disclosure provides a drug delivery device. The drug delivery device is orally ingested by a patient and then activated within the patient's gastrointestinal (GI) tract. Upon activation, a resilient arm within the drug delivery device expands and engages the GI tract wall. A driver then drives a plunger within the drug delivery device, pushing a drug through a channel in the resilient arm and through the patient's GI tract wall. After a period of time, at least a portion of the drug delivery device dissolves, and the drug delivery device passes through the GI tract.

To provide drug delivery devices and methods of controlled drug delivery to a patient.SOLUTION: A drug delivery device may include one or two microchip elements, each of which has a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release apertures are closed off by one or more reservoir caps which can be electrically activated to open the drug release apertures. The drug delivery device also includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced a distance from an exterior wall of the body portion of the microchip element, the outer housing includes the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the exterior wall of the body portion of the microchip element.SELECTED DRAWING: Figure 2

A scalable method of continuous microfluidic synthesis of tannic acid-iron III (TA-FeIII) network (TFN) nanocapsules of a hydrophobic drug; a scalable method of continuous microfluidic synthesis of epigallocatechin-3-gallate iron III (EGCG-FeIII) network, (EFN) nanocapsules; hydrophobic drug nanocapsules synthesized in accordance with the method; and a method of administering a hydrophobic drug to a patient in need thereof by administering to the patient the hydrophobic drug nanocapsules.

An active drug dispensing ophthalmic device can include a plurality of drug reservoirs, each covered by an electrode, and a controller-responder architecture. Electrodissolution of each electrode and the associated drug release can be governed by a controller via a responder. Employing a controller-responder architecture can reduce the number of connections and separate electrical signals required to actively dispense drugs from each of the plurality of drug reservoirs. The controller can be connected to a plurality of responders via a control line bundle and each of the plurality of responders can deliver signals to the electrode(s) covering a portion of a plurality of drug reservoirs. The controller-responder architecture can also employ a composite electrical communication signal to even further decrease the number of electrical connections required from a controller to each of the responders.

Provided is a micro- and nano-fluidic chip, including at least one nanochannel array layer and at least one microchannel array layer that are alternately stacked. The at least one nanochannel array layer includes nanochannels, the at least one microchannel array layer includes input units and / or output units. The input unit includes inlet microchannel arrays and inlets, and the output unit includes outlet microchannel arrays and outlets. The inlet microchannel array includes inlet microchannels, the outlet microchannel array includes outlet microchannels, and the inlet microchannels and the outlet microchannels are connected through the nanochannels.

Provided is a micro- and nano-fluidic chip, including at least one nanochannel array layer and at least one microchannel array layer that are alternately stacked. The at least one nanochannel array layer includes nanochannels, the at least one microchannel array layer includes input units and / or output units. The input unit includes inlet microchannel arrays and inlets, and the output unit includes outlet microchannel arrays and outlets. The inlet microchannel array includes inlet microchannels, the outlet microchannel array includes outlet microchannels, and the inlet microchannels and the outlet microchannels are connected through the nanochannels.

A hollow body has a bottom, an upper end wall, and side walls extending between the bottom and the upper end wall. The upper end wall and side walls are made of metal. The cavity within the hollow body has a volume in the range between 1 picoliter to 1,000 picoliter. The upper end wall comprises at least one opening. The hollow body is suitable for encapsulating small amounts of liquid, or a small micro-electromechanical system, and may be used for the controlled release of pharmaceutical components.